#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14506	16S	1529	1529	99.87	16S.l15.c4.ctg.1	1978	726.3	0	.	n	.	0	A69G	SNP	69	69	A	264	264	G	806	G,A	731,3	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14506	16S	1529	1529	99.87	16S.l15.c4.ctg.1	1978	726.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1645	1645	T	774	T,A	710,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14506	16S	1529	1529	99.87	16S.l15.c4.ctg.1	1978	726.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1379	1379	C	924	C	855	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27160	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3559	760.7	0	.	n	.	0	T695C	SNP	695	695	T	996	996	C	840	C	784	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27160	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3559	760.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2272	2272	C	895	C,T,G	805,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27160	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3559	760.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2898	2898	T	871	T	809	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27160	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3559	760.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2346	2346	A	910	A	849	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2052	folP	855	855	100.0	folP.l15.c30.ctg.1	1655	123.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1082	1084	AGC	204;206;210	A;G;C	191;193;196	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6258	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3319	187.7	1	SNP	p	S91F	1	.	.	271	273	TTC	582	584	TTC	207;206;206	T,A;T;C	194,1;195;197	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6258	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3319	187.7	1	SNP	p	G95N	0	.	.	283	285	GGC	594	596	GGC	208;211;209	G;G;C	197;196;196	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6258	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3319	187.7	1	SNP	p	D95G	1	.	.	283	285	GGC	594	596	GGC	208;211;209	G;G;C	197;196;196	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1724	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1358	126.5	0	.	p	.	0	D79N	NONSYN	235	237	GAT	584	586	AAT	227;228;225	A;A;T	210;213;212	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1724	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1358	126.5	1	SNP	p	G45D	0	.	.	133	135	GGC	482	484	GGC	224;223;224	G;G;C	206;200;201	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	902	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	969	92.5	0	.	n	.	0	A197.	DEL	197	197	A	564	564	A	231	A	216	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5314	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2803	188.7	0	.	p	.	0	E91G	NONSYN	271	273	GAG	527	529	GGG	180;178;175	G;G;G	170;166;163	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5314	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2803	188.7	1	SNP	p	D86N	0	.	.	256	258	GAC	512	514	GAC	189;190;189	G;A;C	180;175;181	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5314	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2803	188.7	1	SNP	p	S87W	0	.	.	259	261	AGT	515	517	AGT	188;186;184	A;G;T	178;177;172	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5314	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2803	188.7	1	SNP	p	S87I	0	.	.	259	261	AGT	515	517	AGT	188;186;184	A;G;T	178;177;172	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5314	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2803	188.7	1	SNP	p	S87R	0	.	.	259	261	AGT	515	517	AGT	188;186;184	A;G;T	178;177;172	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5314	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2803	188.7	1	SNP	p	S88P	0	.	.	262	264	TCC	518	520	TCC	184;181;179	T;C;C	173;166;171	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4652	parE	1986	1986	99.95	parE.l6.c30.ctg.1	2649	175.0	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1577	1579	CAC	225;221;224	C;A;C	212;208;213	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4652	parE	1986	1986	99.95	parE.l6.c30.ctg.1	2649	175.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1526	1528	GGC	232;228;228	G,T;G;C	213,1;211;213	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	3920	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	159.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1303	1305	GCA	212;215;216	G;C;A	195;198;198	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	3920	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	159.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1306	1308	ATC	218;219;218	A;T;C	199;198;200	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	3920	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	159.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1318	1320	GTG	225;223;223	G;T;G	202;198;202	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	3920	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	159.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1318	1320	GTG	225;223;223	G;T;G	202;198;202	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	3920	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	159.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1822	1824	ACC	202;199;201	A;C;C	184;183;184	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	3920	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	159.2	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1876	1878	ACG	201;198;200	A,G;C;G	163,1;168;165	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	3920	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	159.2	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1876	1878	ACG	201;198;200	A,G;C;G	163,1;168;165	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	3920	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	159.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1999	2001	GGC	179;176;180	G;G;C	169;166;167	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	3920	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	159.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2008	2010	GGC	175;176;178	G,C;G;C	160,1;162;164	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	3920	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	159.2	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2026	2028	CTG	166;168;168	C,G;T;G	125,6;122;132	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5786	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3140	183.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1611	1613	CCG	191;192;192	C;C;G	172;179;173	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2608	porA	1146	1146	99.65	porA.l6.c4.ctg.1	1810	143.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	495	495	C	182	C,G	167,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2724	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1380	195.0	0	.	p	.	0	T26A	NONSYN	76	78	ACC	264	266	GCC	218;220;220	G,A;C;C	199,1;204;205	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2724	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1380	195.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	300	302	GAA	245;247;248	G;A;A	231;234;232	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2724	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1380	195.0	0	.	p	.	0	N124S	NONSYN	370	372	AAT	558	560	AGT	207;208;208	A;G;T	194;196;197	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2724	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1380	195.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	588	590	GAT	214;213;217	G;A;T	201;202;206	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2724	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1380	195.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	711	713	TCA	238;236;236	T;C,A;A	217;214,2;218	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2724	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1380	195.0	0	.	p	.	0	A218I	NONSYN	652	654	GCC	840	842	ATC	229;228;229	A;T;C	212;210;211	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2724	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1380	195.0	0	.	p	.	0	F222L	NONSYN	664	666	TTT	852	854	CTT	229;229;231	C;T;T	218;217;219	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2724	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1380	195.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1170	1172	GCA	219;217;213	G;C;A	201;199;195	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2724	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1380	195.0	1	SNP	p	G120K	1	.	.	358	360	AAG	546	548	AAG	203;202;200	A;A;G	189;188;187	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2724	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1380	195.0	1	SNP	p	A121D	1	.	.	361	363	GAC	549	551	GAC	201;201;201	G;A;C	188;187;187	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2724	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1380	195.0	1	SNP	p	D121N	0	.	.	361	363	GAC	549	551	GAC	201;201;201	G;A;C	188;187;187	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	9926	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4719	209.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1962	1964	CAT	227;228;227	C;A;T	214;216;215	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	988	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	936	104.4	1	SNP	p	V57M	1	.	.	169	171	ATG	509	511	ATG	200;200;196	A;T;G	187;189;185	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
